All News

Body mass in younger and older adulthood, and weight gain between these periods, may influence a man?s risk for prostate cancer, and the risk varies among different ethnic populations, report researchers from the University of Hawaii, Honolulu.

A comparison of outcomes of different eras of conservative treatment for localized prostate cancer indicates that overall and prostate cancer-specific survival rates are higher for men diagnosed from 1992 to 2002 compared with men diagnosed in the 1970s and 1980s.

Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to researchers at Brigham & Women's Hospital-Dana Farber Cancer Institute, Boston.

In high-risk men, PSA testing performs optimally when conducted intelligently and combined with prompt, effective, high-quality treatment, according to updated clinical practice guidelines on early detection of prostate cancer from the National Comprehensive Cancer Network.

Since its introduction in 1986, PSA screening has resulted in more than one million men being needlessly diagnosed and treated for prostate cancer, according to a study published online Aug. 31 in the Journal of the National Cancer Institute.

Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to researchers at Brigham & Women's Hospital-Dana Farber Cancer Institute, Boston.

Androgen deprivation therapy leads to an increased risk of bone fractures and other side effects of estrogen deficiency in men with prostate cancer, but those effects can be successfully treated with the use of an oral selective estrogen receptor modulator, suggest the results of a large, prospective, randomized tria presented at the AUA annual meeting in Chicago.

In a phase II study, about 40% of men with clinically localized, high-risk prostate cancer were free of biochemical recurrence at 18 months when treated with neoadjuvant docetaxel (Taxotere) and ketoconazole followed by surgical excision, according to research presented at the AUA annual meeting.